Researchers from Multitude Therapeutics Inc. have reported the preclinical profile of AMT-253, a MUC18-targeting antibody-drug conjugate (ADC) under development for the treatment of melanoma. It comprises the anti-MUC18 humanized antibody pAb253-H linked to T1000 exatecan payload and showed superior antitumor efficacy than the traditional vc-MMAE-based ADC AMT-253-M.
Researchers at Dana-Farber Cancer Institute are advancing a fourth-generation allosteric EGFR inhibitor, EAI-432, to treat non-small-cell lung cancer driven by mutations in the EGFR gene, particularly the L858R mutation.
Proteoglycan glypican-1 (GPC1) is a tumor-associated antigen that is highly expressed in tumor tissues from patients with pancreatic ductal adenocarcinoma (PDAC), while its expression is very low on benign neoplastic lesions, chronic pancreatitis and normal adult pancreatic tissue. Researchers from Centro Di Riferimento Oncologico (CRO Aviano) and L'Università degli studi di Trieste have reported the development and preclinical characterization of AT-101, a novel complement-fixing IgM antibody targeting GPC1, as a potential immunotherapy candidate for the treatment of PDAC.
Patients with end-stage pancreatic ductal adenocarcinoma achieved unprecedented survival rates after being treated with the Engeneic dream vector nanocells, with 88% of patients doubling the historical survival rates, Engeneic Ltd. co-CEO Jennifer MacDiarmid told BioWorld.
Buying out Immunogen Inc. in a whopper cash deal valued at about $10.1 billion, Abbvie Inc. has major plans for an expanded label on the antibody-drug conjugate Elahere (mirvetuximab soravtansine-gynx), already approved for treating platinum-resistant ovarian cancer.
Cancer Research Technology Ltd. has described inhibitors of nuclear factor κB kinase subunit α (CHUK; IKK-1; IKK-α) reported to be useful for the treatment of inflammation and cancer.
KSQ Therapeutics Inc., in collaboration with The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), have announced FDA clearance of an IND application for a phase I/II study of KSQ-001EX, KSQ’s lead engineered tumor-infiltrating lymphocyte (eTIL) program.
Researchers from Shandong Provincial Hospital have published details on the discovery and preclinical characterization of a novel potent microtubule polymerization inhibitor for the treatment of cancer.
RSS
.webp?height=488&t=1677877909&width=650 "Epidermal growth factor receptor (EGFR)")
